Uveitis Treatment Market Worth $687.4 Mn, by 2026 at 4.6% CAGR: Allied Market Research

Rise in prevalence of uveitis, potential drugs in pipeline, and surge in healthcare expenditure worldwide drive the growth of the global uveitis treatment market

News provided by

Allied Market Research

Feb 25, 2020, 09:00 ET

PORTLAND, Oregon, Feb. 25, 2020 /PRNewswire/ -- Allied Market Research recently published a report, titled, "Uveitis Treatment Market by Drug Class (Anti-inflammatory, Antimicrobial Drugs, Immunotherapy & Targeted Therapies, and Others), Disease Type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, and Panuveitis), and Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2019–2026". According to the report, the global uveitis treatment industry was pegged at $500.7 million in 2019 and is expected to reach $687.4 million by 2026, registering a CAGR of 4.6% from 2019 to 2026.

Chief reasons for market fluctuations

Rise in prevalence of uveitis, potential drugs in pipeline, and surge in healthcare expenditure worldwide drive the growth of the global uveitis treatment market. However, unknown etiology of uveitis hampers the market growth. On the contrary, higher number of unmet needs for treatment of uveitis and growing prospects in emerging market are expected to create lucrative opportunities in the near future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/6359

The anti-inflammatory segment held the largest share

The anti-inflammatory segment dominated the global uveitis treatment market in 2019, accounting for nearly two-fifths of the market, owing to easy accessibility of the drugs, increase in prevalence of uveitis, and preferable usage of anti-inflammatory in treatment of the disease. However, the immunotherapy and targeted therapies segment is projected to register the fastest CAGR of 5.8% during the forecast period, owing to cost effectiveness, rise in adoption of immunotherapy and targeted therapies for treatment of severe uveitis, and increase in R&D activities.

The online pharmacies segment to portray fastest growth through 2026

The online pharmacies segment is anticipated to manifest the fastest CAGR of 5.9% during the study period, owing to rise in preference for online purchasing of drugs over the traditional methods, increase in awareness of online pharmacies, and surge in number of Internet users. However, the drug stores & retail pharmacies segment held the largest share in 2019, accounting for nearly three-fifths of the global uveitis treatment market. This is due to increase in number of uveitis patients, surge in number of hospital pharmacies, improvement in structure of hospital pharmacies in the emerging countries such as China and India.

North America held the largest share

The global uveitis treatment market across North America held the largest share in 2019, accounting for more than two-fifths of the market, due to higher prevalence of uveitis, higher healthcare awareness, presence of well-developed healthcare infrastructure and trained medical professionals, and easy accessibility to the therapeutics. However, the market across Asia-Pacific is expected to register the highest CAGR of 6.0% from 2019 to 2026, owing to high population base, growth in prevalence of uveitis treatment systems, and increase in demand for uveitis therapeutics.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/6359

Major market players

AbbVie Inc.
Allergan Plc.
Alimera Sciences, Inc.
Bausch Health Companies Inc. (Bausch & Lomb Incorporated)
Amgen Inc.
EyePoint Pharmaceuticals, Inc.
Clearside Biomedical, Inc.
Novartis AG
Mylan N.V.
Santen Pharmaceutical Co., Ltd.

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter

Get more information: PORTLAND, Oregon Similar Reports:

Asia Pacific Anterior Uveitis Market - Opportunities and Forecasts, 2019-2026

Chagas Disease Treatment Market: Global Opportunity Analysis and Industry Forecast, 2019–2026

Heart Blocks Treatment Market- Global Opportunity Analysis and Industry Forecast, 2019-2026

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
[email protected]